Quick Answer
Bone Biologics Corp reported Net Income of -$3.11 million for fiscal year 2025.
Bone Biologics Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$3.11M +24.4% |
-$4.11M +54.0% |
-$8.95M -502.8% |
-$1.48M +7.8% |
-$1.61M +11.7% |
-$1.82M +46.7% |
| Diluted EPS | -$2.65 +90.8% |
-$28.96 +14.8% |
-$34.01 -9.2% |
-$31.15 | — | — |
| Total Assets | $5.80M +50.1% |
$3.86M +3.3% |
$3.74M -56.0% |
$8.50M +27.3% |
$6.68M | $0.00 -100.0% |
| Cash and Equivalents | — | — | — | — | $6.68M | — |
| Stockholders Equity | $5.38M +54.4% |
$3.48M +19.9% |
$2.91M -51.1% |
$5.95M -9.6% |
$6.58M +148.0% |
-$13.69M -15.4% |
| R&D Expense | $1.06M -50.2% |
$2.13M -69.2% |
$6.91M +337.4% |
$1.58M +1824.9% |
$82.0K -75.9% |
$340.7K -68.9% |
| Operating Income | -$3.23M +23.3% |
-$4.22M +55.3% |
-$9.43M -157.2% |
-$3.67M -232.3% |
-$1.10M -33.7% |
-$825.0K +66.3% |
| Shares Outstanding | 1.80M +264.6% |
492,417 -7.8% |
534,238 +737.1% |
63,820 -99.4% |
10.35M -15.7% |
12.27M -60.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$666.7K | +29.1% | +10.0% |
| Diluted EPS | September 30, 2025 | -$0.37 | +97.4% | +72.2% |
| Total Assets | September 30, 2025 | $6.35M | +56.2% | -9.3% |
| Cash and Equivalents | March 31, 2023 | $6.19M | +6.4% | -17.9% |
| Stockholders Equity | September 30, 2025 | $6.02M | +58.6% | -8.8% |
| R&D Expense | September 30, 2025 | $187.8K | -56.3% | -2.0% |
| Operating Income | September 30, 2025 | -$715.3K | +24.8% | +4.4% |
| Gross Profit | September 30, 2014 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 1.80M | -14.4% | +6.5% |
- Bone Biologics Corp reported Net Income of -$3.11 million for fiscal year 2025.
- Bone Biologics Corp showed an increase of +24.4% in Net Income compared to the prior fiscal year.
- Bone Biologics Corp reported Diluted EPS of $2.65 per share (loss) for fiscal year 2025.
- Bone Biologics Corp showed an increase of +90.8% in Diluted EPS compared to the prior fiscal year.
- Bone Biologics Corp reported Total Assets of $5.80 million for fiscal year 2025.
- Bone Biologics Corp showed an increase of +50.1% in Total Assets compared to the prior fiscal year.
- Bone Biologics Corp reported Cash and Equivalents of $6.68 million for fiscal year 2021.
- Bone Biologics Corp showed an increase of +27547.0% in Cash and Equivalents compared to the prior fiscal year.
- Bone Biologics Corp reported Stockholders Equity of $5.38 million for fiscal year 2025.
- Bone Biologics Corp showed an increase of +54.4% in Stockholders Equity compared to the prior fiscal year.
- Bone Biologics Corp reported R&D Expense of $1.06 million for fiscal year 2025.
- Bone Biologics Corp showed a decrease of -50.2% in R&D Expense compared to the prior fiscal year.
- Bone Biologics Corp reported Operating Income of -$3.23 million for fiscal year 2025.
- Bone Biologics Corp showed an increase of +23.3% in Operating Income compared to the prior fiscal year.
- Bone Biologics Corp reported Shares Outstanding of 1.80 million shares for fiscal year 2025.
- Bone Biologics Corp showed an increase of +264.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: